Overview

• Gilead Sciences announced lenacapavir's success in reducing HIV infection risk by 96% in two Phase 3 clinical trials.
• The trials included diverse populations from multiple countries, with impressive results across all groups.
• Lenacapavir demonstrated significantly higher efficacy compared to the once-daily Truvada, with only two infections in the lenacapavir group versus nine in the Truvada group.
• The drug's twice-yearly injection format addresses adherence challenges associated with daily oral PrEP medications.
• Gilead plans to seek regulatory approval globally by the end of the year, aiming to make lenacapavir widely available for HIV prevention.